bluebird bio Says Continuing To Work Expeditiously To Complete Delayed Filings
Portfolio Pulse from Benzinga Newsdesk
bluebird bio announced it will restate its financial statements for 2022 and 2023, delaying its 2023 Annual Report and Q1 2024 Form 10-Q. The restatement is not expected to impact cash position or revenue. Sterling will oversee the process upon his start date.
May 29, 2024 | 11:09 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
bluebird bio will restate its financial statements for 2022 and 2023, delaying its 2023 Annual Report and Q1 2024 Form 10-Q. The restatement is not expected to impact the company's cash position or revenue. Sterling will oversee the process upon his start date.
The restatement of financials and delay in filings can create uncertainty and negatively impact investor sentiment in the short term, despite no expected impact on cash or revenue. The appointment of Sterling to oversee the process may provide some reassurance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100